Virios reports Q3 net loss $2.6M, cash $9.8M, advances IMC-1 to Phase 3 based on post-hoc FORTRESS analysis

Dogwood Therapeutics, Inc.

2022-Q3 EPS reported -$1.18

Net loss of $2.6M ($0.28 per share) for Q3 2022 vs $4.1M ($0.49) in Q3 2021.
Cash totaled $9.8M as of Sep 30, 2022; company expects to fund operations through end of 2023.
Post-hoc FORTRESS analysis shows significant pain reduction in fibromyalgia patients naive to prior trials/treatment.
Company plans to meet with FDA to discuss advancing IMC-1 into Phase 3 development.
Raised $5M in September 2022 equity capital to support IMC-1 development and working capital.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Dogwood Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $2.6 million, EPS $0.28 basic and diluted net loss per share.

Period: the third quarter ended September 30, 2022
Net income: $2.6 million
EPS: $0.28 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Net loss for the third quarter ended September 30, 2022 was $2.6 million, or $0.28 basic and diluted net loss per share

View on SEC.gov

Browse all earnings releases →

Dogwood Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-017572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.